Moderna and Merck's AI-built cancer vaccine clears phase 3, PYMNTS reports

Sep 14, 2026 · Issue 7 · 1 source, 1 article

PYMNTS reported on 14 September 2026 that the AI-built cancer vaccine Moderna is developing with Merck has passed a phase 3 trial.

Who is affected and how

pharmaceuticals

In personalised mRNA therapy development, the role of AI may be validated at the pivotal stage, so platform strategy deserves reassessment.

Sources

• PYMNTS | Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merckpymnts.com · Sep 14, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.